Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis by Cerchione, Claudio et al.
LETTER TO THE EDITOR
Ruxolitinib rechallenge in combination with hydroxyurea
is effective in reverting cachexia and reducing blood transfusion
demand and splenomegaly symptoms in a patient with primary
myelofibrosis
Claudio Cerchione1 & Ilaria Peluso1 & Davide Nappi1 & Anna Emanuele Pareto1 &
Marco Picardi1 & Vincenzo Martinelli1 & Fabrizio Pane1
Received: 17 December 2016 /Accepted: 28 January 2017 /Published online: 14 February 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Keywords Primarymyelofibrosis . Cachexia . Ruxolitinib .
Hydroxyurea . Splenomegaly
Dear Editor,
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN)
whose pathogenesis mainly involves JAK/STAT signaling;
approximately 65% of patients carry V617F-JAK2 mutation
with a gain-of-function mechanism [1, 2]. Hydroxyurea is
recommended as the first-line therapy for MF in low and
intermediate-1 patients, whereas ruxolitinib, an orally avail-
able and selective JAK2-inhibitor, is recommended in
Internat ional Prognost ic Scor ing System (IPSS)
intermediate-2 and high-risk patients as front-line treatment
of symptoms and splenomegaly in non-transplant candidates
[3].
We describe the case of a 57-year-old Caucasian man with
primary MF (PMF). The patient was 166 cm in height and
weighed 60 kg; before diagnosis, he had been in fair physical
condition. At diagnosis (November 2012), his main symp-
toms were early satiety and a sense of fullness in the left upper
abdomen that rapidly deteriorated into cachexia. His blood
count showed anemia and leukocytosis, and a physical exam-
ination revealed splenomegaly (10 cm from costal margin);
size measured by ultrasound scan [4] was 22 cm (longitudinal
diameter) × 14 cm (transverse diameter) with a spleen volume
of 2700 mL. Bone marrow biopsy demonstrated grade 3 fi-
brosis (MF = 3) and the presence of JAK2-V617Fmutation. In
December 2012, cytoreductive therapy with hydroxyurea (1
and 2 capsules daily on alternate days) was started, obtaining a
stable disease for fewmonths. After 3months, systemic symp-
toms and splenomegaly worsened. The patient was cachectic,
his weight had fallen to 47 kg, and his spleen was of hard
consistency and had enlarged, extending to the iliac fossa.
He had lack of appetite, he was having difficulty eating, and
his quality of life had deteriorated badly. The severity of the
patient’s condition led to the consideration of other treatment
options.
The patient refused allogeneic stem cell transplantation af-
ter becoming aware of transplant-related risks and peri-
transplant mortality. Therefore, treatment with ruxolitinib
was initiated, initially at 10 mg twice daily (bid), and reduced
to 5 mg bid in response to grade 3 thrombocytopenia. The
patient experienced only partial relief from symptoms and,
in September 2014, ruxolitinib was discontinued due to severe
leukocytosis and very poor compliance. After hydroxyurea
was reintroduced to control leukocytosis, there was a consid-
erable increase in the need for blood transfusions over subse-
quent months (up to 8 units/month; Fig. 1) and spleen size
increased, reaching 27.8 cm longitudinal diameter. Following
poor compliance with gastroprotective drugs, the patient re-
quired hospitalization in April 2015 for gastric bleeding, and
hydroxyurea therapy was stopped due to severe anemia and
thrombocytopenia (30,000/mm3).
Hydroxyurea was reintroduced with palliative intent after
1 month and, in June 2015, low-dose ruxolitinib (5 mg bid)
rechallenge was undertaken, in combination with hydroxy-
urea (1 and 2 capsules daily on alternate days for 5 days/
week). The ruxolitinib dose was increased to 10 mg bid after
1 month, and after 2 months (September 2015), the patient
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experienced a dramatic reduction in spleen size with substan-
tial relief from symptomatic splenomegaly (longitudinal diam-
eter 15.6 cm), control of anemia and leukocytosis, and im-
proved nutritional status, with an increase in appetite and an
increase in weight to 55 kg. He regained a decent quality of
life and was able to resume routine activities, such as
shopping.
Resolution of cachexia and substantial improvement in
clinical status continued and, as of May 2016, the patient
was continuing combination treatment with ruxolitinib
(10 mg bid) and hydroxyurea.
Single-agent ruxolitinib is effective in improving spleno-
megaly, systemic symptoms, and overall survival, compared
with placebo and standard treatment, in patients with
intermediate-2 or high-risk MF [5, 6]. As with hydroxyurea,
significant anemia and thrombocytopenia are the most com-
mon side effects, often requiring discontinuation [7].
However, despite the combination of ruxolitinib with a
cytoreductive agent, we obtained control of leukocytosis and
anemia with concurrent increase in platelet count to stable nor-
mal values, without the expected synergic cytotoxic effects. Of
interest, the safe and effective use of combination of ruxolitinib
plus hydroxyurea in reducing platelet count and splenomegaly
in a patient with uncontrolled thrombocytosis on ruxolitinib
monotherapy has been described [8]. Furthermore, in addition
to its primary anti-myeloproliferative action via JAK2 inhibi-
tion, ruxolitinib appears to exert a remarkable improvement in
cachexia status [9], as observed in our case.
In conclusion, combined ruxolitinib plus hydroxyurea ef-
fectively controlled myeloproliferation without worsening
anemia, instead leading to a remarkable decrease in the need
for blood transfusions. Our patient’s cachectic status was
reverted, and overall quality of life dramatically improved.
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